Innate Pharma : Statut Fast Track pour IPH4102
>La FDA accorde le statut de Fast Track pour IPH4102 dans le syndrome de Sézary - Innate Pharma annonce ce matin l’obtention du statut de Fast Track par la FDA pour IPH4102 chez les patients atteints d’un syndrome de Sézary (SS) en rechute ou réfractaire ayant reçu au moins 2 traitements antérieurs. Ce statut accordé par la FDA vise à accélérer le développement et la revue de traitements répondant à des besoins médicaux importants et non satisfaits. Le syndrome de Séz...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.